Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath
-
Narrated by:
-
By:
About this listen
We love to hear from our listeners. Send us a message.
In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development.
Subscribe to the podcast!
Apple | Spotify | YouTube